Premium
Dexamethasone drug delivery system (Ozurdex) for the treatment of refractory diabetic macular oedema: retrospective case series analysis
Author(s) -
AKNIN I,
MELKI L
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.4616.x
Subject(s) - medicine , refractory (planetary science) , ophthalmology , visual acuity , dexamethasone , retrospective cohort study , diabetes mellitus , surgery , physics , astrobiology , endocrinology
Purpose The purpose of this study is to report the clinical outcome of the treatment of DME patients with the Dexamethasone Drug Delivery System (Ozurdex) in clinical practice. Methods This retrospective case series study included 25 consecutive patients (25 eyes) with refractory DME. This preliminary report includes 10 patients who completed a 12 months follow‐up. VA (EDTRS), CRT (OCT) and IOP were assessed at baseline, 7 days, and 1, 6 and 12 months after Ozurdex injection. If necessary, a second implant was injected at 6 and/or 12 month. Results The mean duration of diabetes at baseline was 18.6 years with a mean HbA1c level of 8.97. At baseline the mean VA was 52 letters, mean CRT 467µm and mean IOP 15.9 mmHg. At day 7, the mean VA increased to 62.22 letters (+ 10.22 letters) and the mean CRT decreased to 290.25µm with a mean IOP level of 16.66 mmHg. At month 1: mean VA was maintained to 58.66 letters (+ 6.66 letters) and the CRT continued to decrease to 201µm.The mean IOP slightly increased to 17.83 mmHg (we had 1 case at 24 mmHg) At month 6: mean visual acuity continued to increase to 64.33 letters (+12.33 letters gain). The mean CRT was 281µm with an IOP level of 15.16 mmHg. At month 12: mean visual acuity was maintained to 65.41 letters (2‐line gain: + 13.41 letters), mean retinal thickness and IOP level were normal (200µm and 16.81 mmHg respectively). At month 12: 5 patients (50%) had an improvement of more than 15 letters. 50% of the patients underwent a second injection, and 33% of them Conclusion The present clinical study suggests that intravitreal injection of the dexamethasone drug delivery system (Ozurdex) seems to be effective and well tolerated in eyes with refractory DME